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Abstract 
Background: Implementation science (IS) trials in HIV treatment and prevention evaluate 
implementation strategies that deliver health-enhancing tools such as antiretroviral 
medicines or prevention technologies to those who need them, rather than evaluating the 
tools themselves.  
Method: Opinion piece drawing on a non-systematic review of HIV prevention and 
treatment trials to inform an assessment of five key challenges for IS trials 
Results: Randomised controlled trials (RCTs) are an appropriate design for IS but must 
address five challenges. IS trials must be feasible to deliver, which will require addressing 
challenges in maintaining multisectoral partnerships, strengthening routine data and 
clarifying ethical principles. IS trials should be informative, evaluating implementation 
strategies that are well designed and adequately described, and measuring implementation 
outcomes, coverage of tools and, when appropriate, epidemiological impacts. IS trials 
should be rigorous, striving for internally valid estimates of effect by adopting best 
practices, and deploying optimal non-randomised designs where randomisation is not 
feasible. IS trials should be relevant, considering and documenting how “real-life” is the 
implementation monitoring and whether research participants are representative of the target 
population. Finally, IS trials should be useful, deploying process evaluations to provide 
results that can be used in onward decision making.  
Conclusion: IS trials can help ensure that efficacious tools for HIV prevention and 
treatment have maximum impact in the real world. These trials will be an important 
component of this scientific agenda if they are feasible to deliver and if their results are 
informative, rigorous, relevant and useful. 
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Introduction 
Global efforts to control the HIV epidemic have not yet maximised the population impact of 
prevention and treatment. Condoms prevent HIV transmission, but consistent use remains 
below optimal levels.1 Regular HIV testing helps couples negotiate safer sex, and acts as a 
gateway to care, yet only 75% of people living with HIV (PLHIV) know their status.2 Rapid 
scale up is needed to maximise the impact of oral pre-exposure prophylaxis (PrEP)3 and 
medical male circumcision.4 PLHIV maintained on antiretroviral therapy (ART) experience 
health benefits and suppression of onward transmission,3 yet globally only 47% have a 
controlled viral load.2 Consequently, global HIV incidence remains at nearly 2 million 
infections a year and nearly 1 million deaths were attributable to HIV in 2017.2 
The purpose of medical research should be: “to advance knowledge for the good of society; 
to improve the health of people worldwide; or to find better ways to treat and prevent 
disease.”5 One area of research with the potential to achieve this is IS in the field of 
HIV/AIDS. While definitions of IS differ, it seeks to “advance knowledge” with respect to 
how to organise and deliver HIV prevention and treatment services in real-world settings, 
such that efficacious tools (such as medicines or condoms) are used by a greater proportion 
of those who would benefit from them. Effective implementation strategies identified 
through this agenda reflect “better ways to treat and prevent disease” and have the potential 
to “improve the health of people worldwide”.  
The range of studies that might contribute to this purpose is wide: it may, for example, 
include observational research to estimate the size and location of gaps in coverage of 
efficacious tools, and qualitative research to understand determinants of these gaps. In this 
paper we will discuss one class of IS research: comparative trials of implementation 
strategies to deliver HIV prevention and treatment tools.  
In order for the results of such trials to contribute to the purpose outlined above, we argue 
that scientists must address five challenges related to their design and conduct. These 
challenges are overlapping and sometimes obscured by current thinking. We outline the 
challenges and provide signposts to useful resources to navigate them. We start by providing 
some definitions and terminology that outline the scope of the paper and our view of the 
purpose of IS in HIV treatment and prevention.  
Terminology  
The HIV treatment6 and prevention cascades7 are critical frameworks for our view of HIV 
IS. These frameworks recognise that programmes impact population health through 
individuals’ use of medicines, surgical procedures or behavioural practices that have well-
estimated efficacy and safety. For the treatment cascade, this means ARTs to suppress viral 
load, preventing progression to AIDS and onward HIV transmission. For the prevention 
cascade, it might mean ART for pre- or post-exposure prophylaxis, medical male 
circumcision or condoms, for example. We will use the term ‘tools’ to refer to these active 
ingredients of prevention or treatment which are efficacious when used by those who need 
them.  
Critically, the focus of IS is not on these tools per se. Rather, cascades outline the steps 
necessary for these tools to be used by those who need them. In its simplest form the 
treatment cascade outlines three steps needed for ART to have population impact: first, most 
people living with HIV should be diagnosed; second, they should be linked to care and 
initiated on treatment; and, third, they should be retained in care, adhere to treatment and 
thus be virally suppressed. The principles are similar for the prevention cascade. For HIV 
prevention tools to have population impact, first, they should be accessible; second, people 
at risk should be motivated to use them; and, third, those who use the tools should adhere.7 
We will use the term implementation strategy to refer to any organised programmatic effort 
to achieve HIV prevention or treatment goals by strengthening the cascades through the 
deployment of, for example, health system, behavioural or structural interventions targeted 
at clients and/or providers.8,9 It is these strategies that are the focus of IS, rather than the 
tools. 
What then is an “IS trial”? Individually randomised controlled trials (RCTs) are the gold-
standard for assessing the efficacy of tools.10 RCTs involve random allocation of people to 
two or more “groups” that receive differing “treatments”, with outcomes then compared at a 
later time. We consider that an IS trial is being undertaken if the “treatment” is an 
implementation strategy, and if the trial measures relevant outcomes (we will discuss which 
outcomes may be relevant). For simplicity, we focus on randomised trials (we will briefly 
discuss design options when randomisation is not possible). Implementation strategies often 
(though not always) take the form of complex interventions organised at cluster level (a 
health-facility, community or some other grouping). Consequently, our discussion will focus 
on cluster randomised trials (CRTs).11 As an example, Panel 1 highlights differences in 
emphasis between the HPTN05212 and HPTN 071 (PopART) trials of a tool and an 
implementation strategy, respectively.1314 
What then are the five challenges to the design and conduct of IS trials?  
Our first challenge we label as making IS trials “feasible” to undertake. Scientists must 
argue for the value of investments in research, and we do not wish to limit the ambition of 
implementation scientists in making the case for the trials they wish to conduct. 
Nevertheless, we recognise that decisions about what research to conduct are constrained by 
limited time and resources (especially in the context of a rapidly spreading epidemic that has 
most severely affected low- and middle-income countries). We will identify ways in which 
IS trialists face challenges in getting studies initiated and conducted in an efficient and 
timely manner. Our focus here is on making IS trials feasible to undertake, rather than on the 
feasibility of delivery of the strategies. 
A second and related challenge is that of making IS trials “informative”, by which we mean 
challenges faced by implementation scientists in choosing what strategies to study, how to 
describe these (often complex) strategies to others who wish to learn from the trials they 
conduct, and which outcomes to measure (and, therefore, with time and resource constraints, 
over what time periods and scale to measure them).  
A third challenge is in making the design and conduct of such trials “rigorous”, by which we 
mean that whatever strategies are trialled and outcomes measured, the effect sizes that are 
estimated should be unbiased. We will show how the real-world settings in which IS trials 
are often undertaken work against the desire for rigour in ways that, while not unique, are 
common in IS. These include standardising the application of eligibility criteria, determining 
the most appropriate control treatment, and situations where randomisation is not feasible or 
appropriate. 
Fourth, we discuss the challenging decisions with respect to the design and conduct of IS 
trials that have implications for how “relevant” the findings are. Specifically, we will 
illustrate how decisions about the populations among who outcomes are studied, and the 
delivery and monitoring of the strategies during a trial, can influence how relevant to “real-
life” the findings are perceived to be. 
Fifth and finally, we discuss the challenge of making the outputs of IS trials “useful” for 
others. While a rigorous estimate of effect of a well described and justified implementation 
strategy on an outcome of interest has great value, we will show how the utility of a trial can 
be greatly enhanced if it is also clear how implementation was achieved in practice, how the 
strategy worked to achieve its outcomes (or why it did not), and what would be needed to 
deliver it elsewhere.    
 
Results 
Making IS trials feasible 
We start by identifying three issues which can work against IS trials being undertaken at all. 
First, IS trials involve partnerships between different institutions, including implementing 
NGOs and/or government bodies, academics, evaluators, policy makers and funders.  These 
stakeholders have different incentives for engaging in IS trials and partnerships are fragile to 
maintain. In building these partnerships, one promising process in which all stakeholders 
can engage is in developing a theory of change using participatory approaches.15,16 But 
timing is critical: many evaluation opportunities are lost because the demands on 
implementers to move forward do not allow sufficient time for evaluators to engage, or 
because researchers’ time-intensive processes of writing protocols and seeking and receiving 
ethical approvals work against implementer timelines. As a trial progresses, implementers 
may wish to see detailed process and outcome data, but evaluators may not have the capacity 
to provide these and may be concerned about issues of pragmatism and fidelity to design, 
creating further tensions in such partnerships. There is an urgent need to develop and 
strengthen platforms that bring evaluators and implementers together in ways that foster 
discussion and catalyse this agenda.  
Second, in some settings, investigators may seek to use data from routine data systems 
rather than bespoke research activities to measure outcomes, but in many settings these data 
remain weak. We have the impression that some proponents of IS hold the view that these 
studies must, by definition, use only data from routine systems in tracking outcomes. We do 
not support this view: IS trialists must collect the data necessary to validly answer the 
questions they address: we therefore do not have an opposition to the collection of bespoke 
research data in IS trials. However, we do think that strong routine data systems would 
undoubtedly make it more feasible to undertake IS trials. Further, the use of routine data 
would enhance their value and foster greater investment in these systems. Yet current 
investment in routine data in many settings remains short of what is needed. 
Third, IS trials pose ethical challenges. While the efficacy of the “tool(s)” delivered in such 
trials may be known, there should be equipoise with respect to the potential impact of new 
strategies on the outcomes of interest. Cluster randomised designs pose issues with regard to 
the level at which informed consent must be sought, the ability of participants to leave the 
trial, decisions about the early termination of the trial, and design and analysis 
considerations to ensure the scientific validity of the trial.17 Gopichandran et al. contrast the 
ethical requirements of IS research to clinical research, highlighting where gaps in guidance 
exist and the ethical issues that may arise in the planning, implementation, and post-research 
phases.18 In some situations, group and individual-level consent and participant tracking for 
follow up have been transported from the individual medicine trial to the IS trial. We do not 
(of course) argue for using different ethical standards in IS trials, but we caution that care is 
warranted if such procedures have the unintended consequence of resulting in participants 
becoming unrepresentative of those who might benefit from the interventions in real-life, or 
undermining the conduct of trials completely. Anecdotally, we hear perceptions that ethics 
procedures act as a barrier to the conduct of IS trials, sometimes in ways that do not seem 
central to ensuring the safety of human subjects. For example, in the HPTN 071 (PopART) 
trial participants in Arm A were required to provide individual level research consent to 
receive immediate ART, despite the existence of strong individual level evidence that this 
was good for their own health. We would like to see the launch of a commission on ethics of 
IS that is wide reaching and can support university and other ethical bodies to deal with the 
particular challenges posed by such research.   
Making IS trials informative 
Implementation strategies that are evaluated in trials should be supported by a credible 
theory of change linking the strategy to its intended impact, justified with reference to 
existing knowledge, and supported by formative research. However, there are additional 
challenges in making design decisions about what to trial and what outcomes to measure. 
One tension is in deciding how complex trialled strategies should be. Trialling individual 
components in isolation may not be reflective of real-life programme implementation. Each 
component may generate only a small change in outcomes, such that a prohibitively large 
trial would be needed to detect such a change if studied separately. Additionally, 
components may interact in non-linear ways, making it more important to study than in 
combination. However, where an implementation strategy contains multiple components 
there may be challenges in interpretation. The Botswana Combination Prevention Project 
(BCPP), conducted in Botswana19, and The Sustainable East Africa Research in Community 
Health (SEARCH) trial, conducted in Uganda and Kenya20, illustrate the point. Both trials 
implemented complex strategies involving a range of components (see Panel 2). There were 
significant overlaps, but also important differences between the interventions delivered in 
the intervention arms of these trials, as well as between the contexts in which they were 
implemented. This poses challenges for how to interpret each trial and any differences in the 
results between them. The SEARCH trial did not find a significantly lower HIV incidence in 
Kenya and Uganda in the intervention arm compared to the control, while the BCPP did in 
Botswana. As we will see in the next section, the availability of baseline HIV testing and 
rapid initiation of ART in the control group is one important factor that could explain the 
lack of difference in effect between the two arms of the SEARCH trial. However, the 
differences in the complex set of intervention components being delivered adds another 
layer of complexity to the interpretation of results.  
Further, as interventions grow in complexity and context specificity, they become harder to 
describe in ways that support learning across trials. A range of tools are available to help 
with this. The Standards for Reporting Implementation Studies (StaRI) checklist identifies 
27 items to guide the reporting of both the implementation strategy and the tool being 
implemented,21 as does the Template for Intervention Description and Replication 
(TIDieR).22,23 In developing a taxonomy for behavioural interventions, 73 discrete 
implementation strategies24 and 93 behavioural change techniques have been identified.25 
The Proctor framework suggests specification of the actor, action, dose, temporality, action 
target, implementation outcomes, and justification for implementation strategies,26 and this 
has been further refined using the Capability, Opportunity, Motivation, and Behaviour 
(COM-B) framework.9,27 Implementation strategies should also be grounded in behavioural 
theory which can help justify their likely impact and aid in interpreting findings28,2924  
What outcomes should IS trials measure? Proctor proposes a set of “implementation 
outcomes”: acceptability, adoption, appropriateness, feasibility, fidelity, cost, penetration 
and sustainability.26 In some cases, it may be sufficient to identify whether different 
implementation strategies achieve these indicators of successful delivery. In turn, 
implementation trials may seek to measure the proportion of the target population who are 
successfully using the prevention or treatment tool. High levels of effective use of 
efficacious tools should translate into population impact on the epidemic, for example, 
mortality or HIV incidence. This conversion of efficacy (of tools) to impact (of 
programmes) is, we argue, the ultimate aim of most implementation strategies. But does this 
mean that we always need to study effects on distal outcomes in IS trials? How do we 
balance the need to study public health outcomes of importance with the need to avoid all 
trials being expensive initiatives with many years of follow up? We do not have simple 
answers to these complex questions. Habicht et al. make a distinction between “performance 
evaluations” that measure provision, utilisation, and coverage, and “impact evaluations” that 
measure behavioural or health outcome, suggesting the appropriate outcomes to measure 
depends on the policy context and decisions to be made.30 Smaller trials in a range of 
contexts are needed to test whether novel strategies achieve implementation outcomes. 
However, investigators of these trials will need to be cognisant that the road to 
epidemiological impact cannot be assumed to be simple and this approach puts a greater 
emphasis on modelling projections which may carry debatable assumptions. However, the 
larger trials required to measure epidemiological impacts also have issues in that these huge 
research investments often still occur across relatively small geographies, and can take 
considerable time, and therefore must still confront challenges in translating their findings so 
that they are informative for onward decision making. There must be room in the IS agenda 
for trials at all points along this spectrum.  
Making IS trials rigorous 
RCTs are not rigorous by definition: to draw valid conclusions they must be well conducted 
and correctly interpreted. The design, conduct, analysis and reporting of RCTs have 
improved in recent years in part because of the adoption of the CONSORT statement 10, 
which has an extension for CRTs. While IS researchers sometimes emphasise the difference 
between the types of trials they conduct and clinical trials, in our view CONSORT is 
directly relevant to the vast majority of IS trials, whether randomised or not (and similar 
checklists exist for non-randomised designs31). 
Some methodological challenges will be common to many IS trials. Blinding participants 
and researchers to treatment arm is difficult or impossible. Consequently, an individual’s 
eligibility for participation is often assessed after randomisation rather than before, and staff 
might inadvertently apply the eligibility criteria differently in the two arms. Deaton and 
Cartwright suggest this lack of blinding must be considered a serious threat to trials of social 
interventions.32 Standardised and objective measurement tools are essential to avoid biased 
measurement.  
Another issue is in deciding what strategies to compare to the strategy of interest. A ‘true’ 
control is rarely feasible in an IS trial, since routine practice may change in the standard of 
care arms of such trials, as was the case with the roll-out of universal ART guidelines during 
the HPTN071 (PopART) trial (see Panel 1). Delaying roll out would likely be judged 
unethical. Many settings have other actors providing support to HIV activities that differ 
across geography and time, and it would be unethical to ask them to stop in order to 
guarantee a “true control”. Given the large resources available through a trial, it is desirable, 
and in many cases an ethical imperative, to contribute to strengthening existing activities in 
the areas not receiving the intervention strategy. Some investigators may go further. In the 
SEARCH trial described in Panel 2, it was decided to undertake a community wide HIV 
testing initiative in both intervention and control arms at the start of the trial. Initial 
interpretations have ascribed the lack of difference in HIV incidence between the arms to the 
presence of this “active control”.20 How should the results of the trial be interpreted in this 
situation, and how can we ensure rigorous inference in such trials conducted in real-life 
settings? Again, this is not simple, but investigators need to carefully consider what to 
deliver in standard of care arms of such trials and document the components of intervention 
that differ between arms, as well as changes in delivery in both active and control arms of 
such trials over time. 
Finally, in IS, randomisation may not be feasible. This paper is not the place for a discussion 
of reasons why this may be the case, or of alternatives to randomisation.33,34 Nevertheless, 
we stress that implementation trialists will often need to consult the tool-box of non-
randomised evaluation designs.35 Clear documentation of the implementation strategy and 
prior specification of the (non-randomised) allocation strategy allows the deployment of 
designs such as interrupted time series, non-randomised-controlled studies, or variations on 
the randomised trial such as the stepped wedge trial, or other novel approaches including 
adaptive designs. Although such designs have limitations, they can offer greater validity and 
transparency compared to observational studies.35 Where this is not possible, evaluators 
must rely on analytic approaches to estimate effects where it is hard to avoid making 
multiple untestable assumptions. As for randomised trials, for these designs to produce valid 
results many good practices reflected in CONSORT10 or STROBE31, can and should be 
adopted.   
Making IS trials relevant 
In many areas of science, a continuum is recognised between explanatory and pragmatic 
research, which in turn relates to a distinction between efficacy and effectiveness.36 
Traditionally, the “efficacy” of a tool refers to how effective it is under “ideal” conditions, 
and it is the aim of “explanatory” research to estimate efficacy. In contrast, a tool’s 
“effectiveness” is thought of as its effect in “real-life” conditions, and it is the aim of 
“pragmatic” research to estimate such effects. We find that this distinction between efficacy 
and effectiveness can obscure the important difference between IS and clinical trials. In IS, 
we do not conceive that there are two distinct properties of a given tool (its efficacy in ideal 
conditions, and its effectiveness in the real world). Rather, IS starts from the point of view 
that the extent to which a tool of known efficacy has an effect in a target population depends 
on both the implementation strategy being deployed and the context.  
One way in which IS trials seek to be relevant is by emulating “real-life” conditions. Panel 3 
shows how one trial worked to ensure that the intervention was monitored as it would have 
been in real-life (compared to ensuring perfect fidelity with research resources), and to 
ensure that outcomes were measured among participants intended to benefit in real-life 
(compared to highly selected research participants). Current practice in trials can work 
against these pragmatic aims. For example, we note, anecdotally, a tendency in some 
settings to flexibly support interventions to maximise their chance of success in ways that 
can mean that they are given greater support than would be feasible in “real-life”. 
Importantly, these efforts may remain undocumented as part of the implementation strategy. 
This can compromise the interpretation of the trial and the sustainability of the strategy 
when the trial comes to an end. We have also heard how processes of consent for research 
participants can be perceived to work against ensuring that those enrolled in research are 
representative of those intended to benefit in real-life. For example, individuals from 
marginalized or vulnerable groups may be reticent to provide their personal details and sign 
“legal” consent forms. The time required to explain and obtain informed, signed, opt-in 
consent may be impractical in the settings of such trials.   
Ensuring that trials are conducted in ways that ensure their results are relevant and 
interpretable is challenging, but tools are available to support trialists in designing a trial that 
matches how they intend to use the results.37 The Pragmatic-Explanatory Continuum 
Indicator Summary 2 (PRECIS-2)38 is a tool that encourages investigators to clarify the 
eligibility criteria, recruitment, setting, organisation, flexibility of delivery, and level of 
participant adherence to the intervention. Similarly, the CONSORT extension for pragmatic 
trials39 requires additional information on how participants were chosen, changes that were 
made to the intervention in order to be implemented in the intended setting, how outcomes 
and length of follow up are relevant to participants and decision makers, and a discussion of 
the contextual elements that were essential for implementation and how they might vary in 
other settings. We do not suggest that all IS trials should be conducted in completely real-
life conditions, but it is important for investigators and those who read their research to 
understand this dimension of a trial’s conduct. 
Making IS trials useful 
Information gained in IS trials should contribute to knowledge synthesis, help develop 
theory and support recommendations about what is needed to transfer effective interventions 
to new settings. It is commonplace to assert that while RCTs should be considered the gold 
standard for maximising “internal validity”, they are compromised in the extent to which 
they provide “external validity”.40 We feel this distinction can obscure the more critical 
point for IS. All trials should be rigorous, and thus strive for internal validity. However, 
understanding what can usefully be learnt from an evaluation of an implementation strategy 
in one setting about what is needed in new settings is not a simple case of assessing 
“external validity”. Rather, what is needed is a careful assessment of how and why 
implementation strategies are delivered and achieve their impacts (or do not) in a given 
setting, so that these can be considered in relation to new settings.  
Consequently, undertaking an  integrated process evaluation41 is essential in all IS trials21. 
First, process evaluations should document how implementation occurred, and compare 
what was intended to happen with what actually happened (fidelity to design). Where 
interventions are flexibly delivered, documenting the process for monitoring delivery, 
recording which changes were made, how they were made, and by whom it was decided, 
allows consideration of these issues in future settings. Second, they should investigate how 
participants respond to the interventions in terms of their acceptability and accessibility and 
track behavioural pathways of change. Third, they should document salient characteristics of 
the context in which the implementation strategy was delivered that would influence 
whether the intervention works as intended. For example, what health system characteristics 
were necessary to support a particular intervention being delivered, or what structural factors 
influenced how safe sex messages could be delivered? Process evaluations are, by nature, 
mixed-method endeavours involving collaboration with social and behavioural scientists.42 
STaRI includes guidance on reporting the methods and results of process evaluations. To 
illustrate the value of process evaluation, consider the Intervention with Microfinance for 
AIDS and Gender Equity (IMAGE) trial described in Panel 4.43  
Cartwright and Hardie seek to help policy makers improve evidence-based policy and 
encourage consideration of “support factors” that will help decide whether what worked 
“there” will work “here”.44 Bonell argues that trials of social interventions should be seen as 
“realist” as opposed to “positivist” in nature,45 and are an ideal opportunity to study 
mechanisms of change and contextual factors that influence whether interventions achieve 
their aims in a given setting.  Cartwright suggests discussing interventions at a higher level 
of abstraction than a detailed minutiae description of the precise components of the 
intervention, a way of thinking sometimes termed “middle-range theory”.46 Finally, the 
Consolidated Framework for Implementation Research (CFIR) provides 39 ways to 
characterise five contextual domains: characteristics of the intervention; the political, social, 
or economic context within which implementation is occurring; the structure within which 
implementation will take place; characteristics of the individuals involved in the process; 
and the activities that allow the process of implementation to unfold, such as planning and 
execution.47 
Conclusion 
Cutting edge science, in which randomised trials have played a critical role, has supported 
the identification of an array of tools that prevent or treat HIV infection if used by those who 
need them. We wish to see a comparable level of critical thinking given to programme 
implementation efforts that ensure these tools have an impact on the epidemic at large. Some 
of the scientific challenges in evaluating new drugs and new implementation strategies are 
similar and we argue that the RCT is an appropriate design in IS. Nevertheless, we have 
outlined challenges implementation scientists confront in undertaking trials that are feasible, 
informative, rigorous, relevant and useful and offer some thoughts on how to address these 
challenges, summarised in Table 1. IS is the critical area where progress will support 
achievement of the sustainable development goals, not just in relation to HIV but across all 
areas of global health, and we posit that IS trials will be an essential part of this scientific 
agenda if we can face up to these challenges. 
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Panel 1: Differences in emphasis of an individually randomised clinical trial of a 
biomedical tool and a cluster randomised trial of an implementation strategy: the 
HPTN 052 and HPTN 071 (PopART) trials 
 
The HPTN 052 trial was an individually randomised trial to establish the biological 
efficacy of a “tool”: ART initiated immediately regardless of CD4 count, to reduce the 
viral load and consequently prevent onward transmission of HIV. Its purpose was to 
generate scientific proof of the concept that immediate antiretroviral treatment can reduce 
the infectiousness of HIV-infected individuals. Newly diagnosed HIV-positive individuals 
in serodiscordant sexual partnerships were randomly assigned to two trial arms: 
immediate initiation of ART, and standard of care, which delayed the initiation of ART 
until CD4 count was less than 250 cells/mm3. HIV transmission rates to uninfected 
partners were compared between the arms. Its purpose was to generate scientific proof of 
the concept that immediate antiretroviral treatment can reduce the infectiousness of HIV-
infected individuals. It found a 93% reduction in the sexual transmission of HIV in HIV-
serodiscordant couples.12 
 
By contrast, the HPTN071 (PopART) trial was a cluster randomised trial with three arms 
(A, B, C), randomised at community level in South Africa and Zambia, each of which 
reflected a different “implementation strategy”.13 The implementation strategy in Arm A 
used community HIV care providers who travelled house to house providing HIV 
counselling and testing, and linking HIV negative individuals to prevention services and 
HIV positive individuals to clinics for treatment, as a strategy to increase the use of HIV 
prevention and treatment tools among people. In the clinic, HIV-positive individuals were 
offered immediate ART regardless of their CD4 count. The strategy was identical in arm 
B, except that at the clinic HIV positive individuals were offered ART according to 
national guidelines (which changed over the course of the trial). Arm C was the standard 
of care arm. The HPTN071 (PopART) was designed as a CRT because the 
implementation strategy could not meaningfully be randomised to individual people, and 
there was equipoise with respect to the effects of interest on cluster-level outcomes such 
as community HIV incidence. The trial found a 30% and significantly lower HIV 
incidence in Arm B compared to Arm C, and a smaller and non-significant 7% lower HIV 
incidence in Arm A compared to Arm C. 
 
  
Panel 2: Complex interventions and active control arms: the SEARCH and BCPP 
cluster randomised trials 
 
The BCPP and SEARCH trials were cluster randomised trials of universal test and treat 
(UTT) strategies for HIV prevention. The BCPP trial found a 30% lower HIV incidence 
in the intervention compared to the control arm, while the SEARCH trial found 
reductions in HIV incidence in both arms, but no difference between the arms. The 
implementation strategies in both trials had many components, with much overlap but 
also some differences,48 for example, in the SEARCH trial a multi-disease health 
campaign (“health fair”) was conducted, while in the BCPP trial testing was carried out 
for HIV only. In the SEARCH trial, the health fair and the home-based testing rounds 
were delivered at baseline in both intervention and control arms.  
 
Trial BCPP SEARCH 
Country Botswana Kenya / Uganda 
HIV 
Prevalence 29% 4-19% 
















































Panel 3: Striving for relevance: the SAPPHIRE trial 
 
The Sisters Antiretroviral therapy Programme for Prevention of HIV-an Integrated 
Response (SAPPH-IRe) trial49,50 was conducted to establish the impact of an enhanced 
package of community mobilisation and clinical service activities designed to increase 
female sex workers’ (FSW) engagement in HIV treatment and prevention services on the 
proportion of all female sex workers with detectable HIV. In the intervention arm, FSW 
received usual care services, plus an enhanced program of community mobilisation and 
on-site provision of ART to increase access to and uptake of HIV treatment and care 
services.  In the standard of care arm, the WHO standard programme for FSW51 was 
delivered through the national “Sisters With a Voice” programme, which involves HIV 
testing and counselling, referral to government services for ART, and other HIV and STI 
care services. The trial found improvements in viral suppression among female sex 
workers in both arms of the trial but no difference between the arms. 
 
Two factors contributed to making the trial findings relevant to a “real-life” setting, as 
described in the table below. 
 
Sample 
The investigators sought to measure the impact of the intervention 
not on a convenience sample of sex workers, perhaps those most 
easily recruited through the clinics and likely to attend the 
intervention sessions. Rather, they sought to recruit a representative 
sample of FSW among whom there would be diverse levels of 
interest in, engagement with and adherence to the intervention 
packages. Since no sampling frame of sex workers existed, 
implementing this approach required the use of novel sampling 
strategies (respondent driven sampling), and careful analysis to 
report the trial aligned with CONSORT principles.49 
Monitoring 
The intervention was monitored by the implementation team using 
routine data and management structures as it would have been in 
routine practice. This meant that when these process data were 
analysed at the end of the trial, it showed that not all aspects of the 
intervention were delivered as intended. Far from reflecting a 
failure of the trial, this helped identify the intervention components 
that may not be applicable in routine practice and provided an idea 







Panel 4: The value of process evaluation: the IMAGE trial 
 
The IMAGE intervention combined microfinance-based lending with a gender and HIV 
training programme aimed at empowering women in South African villages. The aims 
were to reduce intimate partner violence and HIV infection rates. The microfinance 
component provided loans to women to establish income-generating businesses and 
required that they meet fortnightly to manage these loans. These fortnightly meetings 
provided a platform for delivering the gender and HIV training programme where training 
sessions about gender roles, domestic violence, safe sexual practices, and HIV infection 
took place. Trained women would then go on to participate in community mobilisation 
activities to increase condom use and promote safe sexual behaviours to the young men 
and women of their households and communities. IMAGE reduced levels of intimate 
partner violence among participating women, but was not successful in changing levels of 
condom use or HIV infection among young people in their households or communities.52  
 




Data collection Qualitative data: researchers’ 
observation; focus group discussions; 
interviews with implementers, 
participants, and those who dropped 
out of the programme 
Quantitative data: 
recruitment, attendance and 
retention 
Results ► The training programme was well attended and highly valued. 
► Participation in community mobilisation was possible and 
rewarding for some women, but many were not motivated or faced 
difficulty in finding the time to engage in these activities.  
► Only 10% of households in target communities directly 
participated in the intervention.  
Interpretation ► The lack of effect on condom use and HIV transmission among 
members of the household and community could be explained by 
challenges in community mobilisation, rather than by failure of the 
training.  
► Interviews with providers both within and beyond the study 
setting revealed that the approach to training in the course of the 
trial was unlikely to be either sustainable in situ or transferrable to 
other microfinance organisations because of its need for high level 
skills and quality assurance practices that would not be widely 
available in many microfinance organisations.  
►This insight made it possible to develop delivery models that 
would be transferrable to other settings. 
 
Table 1: Summary of the challenges in the design and conduct of IS trials for HIV 
prevention and treatment  
 
Challenge Description Suggestions for how to address the challenges 
Feasibility 
Partnerships for IS trials 
are complex and fragile; 
multiple stakeholders with 
different incentives and 
timelines 
Develop and strengthen platforms to build 
partnerships (e.g. participatory approaches to co-
develop Theories of Change). 
Routine data are weak; 
bespoke research data can 
be complex and expensive 
to collect 
Investments in strengthening routine data 
systems are needed. 
Ethical norms have been 
imported from clinical and 
social science research and 
can create barriers 





to trial and how complex 
they should be  
Consider balance between complexity and 
simplicity: trialling individual components in 
isolation is not reflective of real-life programmes 
and would require large trials to detect change; 
multiple components pose challenges in 
interpretation. 
Complex implementation 
strategies can be difficult 
to describe 
Use available tools to describe interventions, 
such as: 
► The Standards for Reporting Implementation 
Studies (StaRI) checklist 
► Template for Intervention Description and 
Replication (TIDieR) 
► The Proctor framework: specification of the 
actor, action, dose, temporality, action target, 
implementation outcomes, and justification for 
implementation strategies. 
Which outcomes to 
measure? Not all trials can 
be very large and study 
both proximate and distal 
outcomes 
► Consider the policy context and what 
decisions are to be informed or strengthened by 
evidence 
► Consider balance: smaller trials in a range of 
contexts are needed to measure the effect of 
strategies on implementation outcomes but 
requires strong assumptions for epidemiological 
impact; larger trials are needed to measure 
epidemiological impacts but occur across small 
geographies and can take considerable time. 
Rigor Are the rules of RCTs 
relevant to IS trials? 
Most of the time, the CONSORT can be used to 
guide IS trials. 
Lack of blinding of 
participants; eligibility 
assessed after 
randomisation; risk of 
applying the eligibility 
criteria differently in the 
two arms 
Use of standardised and objective measurement 
tools to avoid biased measurement. 
Lack of a “true control” 
► Carful consideration of what to deliver in the 
standard of care arm 
► Document the components that differ between 
arms, and the changes in delivery in both active 
and control arms over time. 
Randomisation may not be 
feasible in some settings 
► Use quasi-experimental and alternative trial 
designs 
► Clear documentation of the implementation 
strategy and prior specification of the non-
randomised allocation 
Relevance 
The distinction between 
efficacy and effectiveness 
is not clear in IS 
► The extent to which a tool of known efficacy 
has an effect in a target population depends on 
both the implementation strategy and the context 
► Focus on the effectiveness of the 
implementation strategy rather than the efficacy 
of the tool 
Deciding how pragmatic 
the trial should be is not 
simple 
Where possible, recruit populations intended to 
benefit in real-life, monitor the intervention as it 
would be in routine practice, and use tools (e.g. 
PRECIS-2) to match design and conduct to the 
intended use of results. 
Usefulness 
What happens in practice 
may differ from the 
intended implementation 
Integrate a process evaluation to document how 
implementation occurred, how participants 
respond to the interventions, and the salient 
characteristics of the context in which the 
implementation strategy was delivered 
Clients may respond in a 
range of ways to 
interventions 
How to learn from an 
evaluation of an 
implementation strategy in 
one setting about what is 





1.  Steiner MJ, Cates W, Warner L. The real problem with male condoms is nonuse. Sex 
Transm Dis. 1999;26(8):459-462. 
2.  UNAIDS. AIDS Statistics—2018 Fact Sheet. Geneva: UNAIDS; 2018. 
3.  World Health Organisation. Guidance on Couples HIV Testing and Counselling 
Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant 
Couples: Recommendations for a Public Health Approach. Geneva: WHO; 2012. 
4.  Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in 
sub-Saharan Africa: a systematic review and meta-analysis. Aids. 2000;14(15):2361-
2370. 
5.  What is the purpose of medical research? Lancet. 2013;381(9864):347. 
doi:10.1016/S0140-6736(13)60149-X 
6.  Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of 
engagement in HIV care and its relevance to test-and-treat strategies for prevention of 
HIV infection. Clin Infect Dis. 2011;52(6):793-800. doi:10.1093/cid/ciq243 
7.  Hargreaves JR, Delany-Moretlwe S, Hallett TB, et al. The HIV prevention cascade: 
integrating theories of epidemiological, behavioural, and social science into 
programme design and monitoring. Lancet HIV. 2016;3(7):e318-e322. 
doi:10.1016/S2352-3018(16)30063-7 
8.  Krishnaratne S, Hensen B, Cordes J, Enstone J, Hargreaves JR. Interventions to 
strengthen the HIV prevention cascade: a systematic review of reviews. Lancet HIV. 
2016;3(7):e307-e317. doi:10.1016/S2352-3018(16)30038-8 
9.  Hickey MD, Odeny TA, Petersen M, et al. Specification of implementation 
interventions to address the cascade of HIV care and treatment in resource-limited 
settings: A systematic review. Implement Sci. 2017;12(1):1-15. doi:10.1186/s13012-
017-0630-8 
10.  Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for 
reporting parallel group randomised trials. BMC Med. 2010;8(1):18. 
11.  Eccles M, Grimshaw J, Campbell M, Ramsay C. Research designs for studies 
evaluating the effectiveness of change and improvement strategies. Qual Saf Heal 
Care. 2003;12. doi:10.1136/qhc.12.1.47 
12.  Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with Early 
Antiretroviral Therapy. N Engl J Med. 2011;365(6):493-505. 
doi:10.1056/NEJMoa1105243 
13.  Hayes R, Ayles H, Beyers N, et al. HPTN 071 (PopART): rationale and design of a 
cluster-randomised trial of the population impact of an HIV combination prevention 
intervention including universal testing and treatment - a study protocol for a cluster 
randomised trial. Trials. 2014;15:57. doi:10.1186/1745-6215-15-57 
14.  Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on 
HIV Incidence — HPTN 071 (PopART). N Engl J Med. 2019;381(3):207-218. 
doi:10.1056/NEJMoa1814556 
15.  Breuer E, De Silva MJ, Fekadu A, et al. Using workshops to develop theories of 
change in five low and middle income countries: lessons from the programme for 
improving mental health care (PRIME). Int J Ment Health Syst. 2014;8(1):15. 
16.  Peters DH, Bhuiya A, Ghaffar A. Engaging stakeholders in implementation research: 
lessons from the Future Health Systems Research Programme experience. 2017. 
17.  Hutton JL. Are distinctive ethical principles required for cluster randomised controlled 
trials? Stat Med. 2001;20. doi:3.0.CO;2-D 
18.  Gopichandran V, Luyckx VA, Biller-Andorno N, et al. Developing the ethics of 
implementation research in health. Implement Sci. 2016;11(1):161. 
doi:10.1186/s13012-016-0527-y 
19.  Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded 
Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med. 
2019;381(3):230-242. doi:10.1056/NEJMoa1812281 
20.  Havlir D V., Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use 
of a Community Health Approach in Rural Africa. N Engl J Med. 2019;381(3):219-
229. doi:10.1056/NEJMoa1809866 
21.  Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation 
Studies (StaRI) Statement. BMJ. 2017;356. doi:10.1136/bmj.i6795 
22.  Better reporting of interventions: template for intervention description and replication 
(TIDieR) checklist and guide. doi:10.1136/bmj.g1687 
23.  Cotterill S, Knowles S, Martindale AM, et al. Getting messier with TIDieR: 
Embracing context and complexity in intervention reporting. BMC Med Res Methodol. 
2018;18(1):12. doi:10.1186/s12874-017-0461-y 
24.  Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation 
strategies: Results from the Expert Recommendations for Implementing Change 
(ERIC) project. Implement Sci. 2015;10(1):1-14. doi:10.1186/s13012-015-0209-1 
25.  Michie S, Carey RN, Johnston M, et al. From Theory-Inspired to Theory-Based 
Interventions: A Protocol for Developing and Testing a Methodology for Linking 
Behaviour Change Techniques to Theoretical Mechanisms of Action. Ann Behav Med. 
2016:1-12. doi:10.1007/s12160-016-9816-6 
26.  Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for 
specifying and reporting. Implement Sci. 2013;8(1):139. doi:10.1186/1748-5908-8-139 
27.  Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for 
characterising and designing behaviour change interventions. Implement Sci. 2011;6. 
doi:10.1186/1748-5908-6-1 
28.  Birken SA, Powell BJ, Shea CM, et al. Criteria for selecting implementation science 
theories and frameworks: Results from an international survey. Implement Sci. 
2017;12(1):1-9. doi:10.1186/s13012-017-0656-y 
29.  Nilsen P. Making sense of implementation theories, models and frameworks. 
Implement Sci. 2015;10:53. doi:10.1186/s13012-015-0242-0 
30.  Habicht JP, Victora CG, Vaughan JP. Evaluation designs for adequacy, plausibility 
and probability of public health programme performance and impact. Int J Epidemiol. 
1999;28(1):10-18. doi:10.1093/ije/28.1.10 
31.  von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting 
observational studies. J Clin Epidemiol. 2008;61(4):344-349. 
doi:10.1016/j.jclinepi.2007.11.008 
32.  Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled 
trials. Soc Sci Med. 2018;210:2-21. doi:10.1016/j.socscimed.2017.12.005 
33.  Bonell CP, Hargreaves J, Cousens S, et al. Alternatives to randomisation in the 
evaluation of public health interventions: Design challenges and solutions. J Epidemiol 
Community Health. 2011;65(7). doi:10.1136/jech.2008.082602 
34.  Cousens S, Hargreaves J, Bonell C, et al. Alternatives to randomisation in the 
evaluation of public-health interventions: Statistical analysis and causal inference. J 
Epidemiol Community Health. 2011;65(7). doi:10.1136/jech.2008.082610 
35.  Davey C, Boulay M, Hargreaves JR. Strengthening Nonrandomized Studies of Health 
Communication Strategies for HIV Prevention. JAIDS J Acquir Immune Defic Syndr. 
2014;66:S271-S277. doi:10.1097/QAI.0000000000000232 
36.  Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic–explanatory continuum 
indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 
2009;62(5):464-475. 
37.  Zwarenstein M, Treweek S, Loudon K. PRECIS-2 helps researchers design more 
applicable RCTs while CONSORT Extension for Pragmatic Trials helps knowledge 
users decide whether to apply them. J Clin Epidemiol. 2017;84(Supplement C):27-29. 
doi:https://doi.org/10.1016/j.jclinepi.2016.10.010 
38.  Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The 
PRECIS-2 tool: designing trials that are fit for purpose. bmj. 2015;350:h2147. 
39.  Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic 
trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. 
doi:10.1136/BMJ.A2390 
40.  Rothwell PM. External validity of randomised controlled trials:“to whom do the results 
of this trial apply?” Lancet. 2005;365(9453):82-93. 
41.  Moore G, Audrey S, Barker M, Bonell C, Hardeman W, Moore L, O’Cathain A, Tinati 
T, Wight D BJ. Process Evaluation of Complex Interventions: UK Medical Research 
Council (MRC) Guidance.; 2014. 
42.  Palinkas L a, Horwitz SM, Chamberlain P, Hurlburt MS, Landsverk J. Mixed-methods 
designs in mental health services research: a review. Psychiatr Serv. 2011;62(3):255-
263. doi:10.1176/appi.ps.62.3.255 
43.  Intervention T, Study GE, Study I, Africa S. Study Protocol The Intervention with 
Microfinance for AIDS and Gender Equity Study ( IMAGE Study ) : An integrated 
community randomised trial of a structural intervention to prevent HIV and gender-
based violence in South Africa. Health Policy (New York). 2005;1:1-68. 
44.  Cartwright N, Hardie J. Evidence-Based Policy: A Practical Guide to Doing It Better. 
Oxford University Press; 2012. 
45.  Bonell C, Fletcher A, Morton M, Lorenc T, Moore L. Realist randomised controlled 
trials: A new approach to evaluating complex public health interventions. Soc Sci Med. 
2012;75(12):2299-2306. doi:10.1016/j.socscimed.2012.08.032 
46.  Davey C, Hargreaves J, Hassan S, et al. Designing evaluations to provide evidence to 
inform action in new settings. 2018. 
47.  Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implement Sci. 2009;4. 
doi:10.1186/1748-5908-4-50 
48.  Perriat D, Balzer L, Hayes R, et al. Comparative assessment of five trials of universal 
HIV testing and treatment in sub-Saharan Africa. J Int AIDS Soc. 2018;21(1). 
doi:10.1002/jia2.25048 
49.  Hargreaves JR, Fearon E, Davey C, Phillips A, Cambiano V, Cowan FM. Statistical 
design and analysis plan for an impact evaluation of an HIV treatment and prevention 
intervention for female sex workers in Zimbabwe: a study protocol for a cluster 
randomised controlled trial. Trials. 2016;17:6. doi:10.1186/s13063-015-1095-1 
50.  Cowan FM, Davey C, Fearon E, et al. Targeted combination prevention to support 
female sex workers in Zimbabwe accessing and adhering to antiretrovirals for 
treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial. Lancet 
HIV. 2018;5(8):e417-e426. doi:10.1016/S2352-3018(18)30111-5 
51.  WHO. Preventing HIV in Sex Work Settings in Sub-Saharan Africa. World Health 
Organization; 2011. 
52.  Pronyk PM, Hargreaves JR, Kim JC, et al. Effect of a structural intervention for the 
prevention of intimate-partner violence and HIV in rural South Africa: a cluster 
randomised trial. Lancet. 2006;368(9551). doi:10.1016/S0140-6736(06)69744-4 
53.  Hargreaves J, Hatcher A, Strange V, et al. Process evaluation of the Intervention with 
Microfinance for AIDS and Gender Equity (IMAGE) in rural South Africa. Health 
Educ Res. 2010;25(1). doi:10.1093/her/cyp054 
 
